CMV infection is endemic in most countries of the world. It is likely to take severe forms in immunocompromised individuals hemodialysis patients, given that the seroprevalence is high among the general population. Our study is a prospective description of the seroprevalence of cytomegalovirus among chronic hemodialysis patients in Marrakesh through a serie of 5120 patients treated in the hemodialysis centers of Marrakesh, who’s their serum is analyzed in Virology department of the Military Hospital Avicenne, over a period of 64 months, from September 2015 to January 2021. Serological test for the presence of IgG and IgM anti CMV, was performed by immunoassay technique chemiluminescent microparticle (CMIA), by ARCHITECT (ABBOTT DIAGNOSTIC). The prevalence of IgG and IgM anti-CMV was 98% and 0.6% respectively. The mean age of patients with CMV IgG positive was 53 years. The sex ratio was 1.04. Arterial hypertension was present in 52% of CMV positive patients, followed by diabetes (29%). Among our patients, 19% have been on hemodialysis for less than 2 years, while 42% have been treated for 2 to 5 years. 68% of CMV-positive patients are on hemodialysis 3 times a week versus 32% on 2 times. The prevalence of CMV is 63% in transfused patients with an average recurrence of 2 transfusions. Regarding the type of blood transfused, 99.7% of the patients were transfused with standard blood, against 16 patients transfused with leukoreduced blood. We recommend blood transfusion leukodepleted in the hemodialysis population to reduce the risk of transfusion transmission CMV.